Back to top
more

Gilead Sciences (GILD)

(Real Time Quote from BATS)

$86.74 USD

86.74
113,861

+0.02 (0.02%)

Updated Oct 21, 2024 09:52 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Celgene (CELG) to Acquire Juno Therapeutics for $9 Billion

by Zacks Equity Research

Celgene is set to acquire Juno Therapeutics for $87 per share or a total value of $9 billion to strengthen its position in the cellular immunotherapy space.

    Gilead Collaborates with Pfizer for Yescarta Combo Study

    by Zacks Equity Research

    Kite, a Gilead Company (GILD), announced that it inked a clinical trial collaboration with Pfizer, for combination study.

      The Zacks Analyst Blog Highlights: Apple, JPMorgan, AbbVie, Gilead and Simon Property Group

      by Zacks Equity Research

      The Zacks Analyst Blog Highlights: Apple, JPMorgan, AbbVie, Gilead and Simon Property Group

        Juno Hits 52-Week High on Celgene's Rumored Buyout Interest

        by Zacks Equity Research

        Juno Therapeutics, Inc.'s (JUNO) shares hit a 52 week high on rumors of the company being acquired by Celgene Corporation.

          Novartis sBLA for CAR-T Therapy Kymriah Accepted by FDA

          by Zacks Equity Research

          Novartis (NVS) gets a significant boost with the FDA approval of CAR-T Therapy Kymriah and the company is now looking to expand the therapy's label.

            Arpita Dutt headshot

            3 Top-Ranked Drug Stocks that are Broker Favorites

            by Arpita Dutt

            With the pharma and biotech sector performing well in 2017, here is a look at three drug stocks including Vertex (VRTX) that are broker favorites.

              Mark Vickery headshot

              Top Research Reports for Apple, JPMorgan & AbbVie

              by Mark Vickery

              Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), JPMorgan (JPM) and AbbVie (ABBV).

                Is Celgene (CELG) Looking to Take Over Juno Therapeutics?

                by Zacks Equity Research

                There are reports that Celgene (CELG) is in talks to acquire Juno Therapeutics to strengthen its portfolio given the recent series of setbacks.

                  Arpita Dutt headshot

                  Biotech Stock Roundup: Juno Surges on Acquisition Rumor, Concert Down on Patent News

                  by Arpita Dutt

                  Is Celgene (CELG) in talks with Juno regarding a possible acquisition deal? This was the main news in the biotech sector this week.

                    Can Biotech Keep Last Year's Momentum Alive in 2018?

                    by Zacks Equity Research

                    The biotech sector performed impressively in 2017 and the momentum is expected to continue in 2018 driven by new drug approvals. Acquisitions will also remain in focus.

                      Arpita Dutt headshot

                      Biotech Stock Roundup: Celgene to Acquire Impact, J.P. Morgan Healthcare Conference in Focus

                      by Arpita Dutt

                      Focus this week was on preliminary results and 2018 outlooks provided by several companies including Celgene (CELG) at a healthcare conference.

                        Galapagos Reports Topline Data From Osteoarthritis Study

                        by Zacks Equity Research

                        Galapagos' (GLPG) osteoarthritis candidate, GLPG1972, reduces level of ARGS neoepitope, a cartilage breakdown biomarker, by more than half in an early stage study.

                          Celgene to Acquire Impact Biomedicines to Boost Pipeline

                          by Zacks Equity Research

                          Celgene (CELG) announced that it will acquire Impact Biomedicines to bolster its oncology pipeline given the recent series of setbacks.

                            Arpita Dutt headshot

                            3 Biotech and Pharma Stocks with FDA Catalysts this January

                            by Arpita Dutt

                            2017 saw the FDA approving 46 novel drugs as well as path-breaking treatments like Novartis's (NVS) Kymriah and Gilead's Yescarta. Here is a look at three companies expecting a decision this January.

                              Intercept (ICPT) Stock Loses Sheen in 2017: What Lies Ahead?

                              by Zacks Equity Research

                              Intercept (ICPT) had a tough time in 2017 after news of death were out related to lead drug's Ocaliva's dosing. We do not expect a phenomenal revival in 2018 either.

                                Celgene (CELG) in Troubled Waters in '17: What Does 2018 Hold?

                                by Zacks Equity Research

                                Celgene's (CELG) stock has been under pressure due to pipeline setbacks. We expect an acquisition in the offing to bolster its portfolio.

                                  Arpita Dutt headshot

                                  5 of the Best-Performing Biotech Stocks of 2017

                                  by Arpita Dutt

                                  With 2017 coming to an end, it is time to take a look at the performance of the biotech sector and some of the best-performing biotech stocks including XOMA (XOMA).

                                    4 Biotech Stocks Ready to Crush the Market in 2018

                                    by Zacks Equity Research

                                    The biotech sector has performed well in 2017 and we expect the momentum to continue in 2018 driven by new drug approvals. Here, we list stocks which might be worth adding to your biotech portfolio for 2018.

                                      Arpita Dutt headshot

                                      3 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2018

                                      by Arpita Dutt

                                      Immuno-oncology was a key focus area in 2017 - will it remain so in 2018 as companies like Juno (JUNO) progress with their pipelines?

                                        CAR T Stocks in Focus with ASH 2017 Meet: GILD, JUNO & More

                                        by Zacks Equity Research

                                        The CAR-T therapy space has been in spotlight since Aug 2017 and the recent ASH meeting had further put focus on the same.

                                          Arpita Dutt headshot

                                          Biotech Stock Roundup: ASH Data in Focus, Gilead to Buy Cell Design Labs

                                          by Arpita Dutt

                                          The annual meeting of the American Society of Hematology was the key highlight this week with several companies like bluebird (BLUE) presenting data on their investigational treatments.

                                            Juno Reports Additional Data on CAR-T Therapy, Shares Drop

                                            by Zacks Equity Research

                                            Juno (JUNO) releases additional results from the ongoing phase I study of its chimeric antigen receptor T-cell (CAR-T) therapy candidate, JCAR017.

                                              Bluebird's Shares Jump on Strong Data for CAR-T Therapy

                                              by Zacks Equity Research

                                              bluebird (BIRD) announced updated results from the ongoing phase I study of its chimeric antigen receptor T-cell (CAR-T) therapy candidate- bb2121.

                                                Gilead (GILD) Posts Updated Data on CAR-T Therapy Yescarta

                                                by Zacks Equity Research

                                                Gilead (GILD) announced follow-up data from a phase II study, on its CAR-T therapy, Yescarta for treatment of refractory large B-cell lymphoma.

                                                  Novartis Reports Updated Results from Kymriah's JULIET Study

                                                  by Zacks Equity Research

                                                  Novartis (NVS) announced updated results from the JULIET study, which show Kymriah sustained complete responses at six months in adults with relapsed or refractory diffuse large B-cell lymphoma.